Phase 1 studies are the springboard for advancing new cancer treatments. Through phase 1 studies, the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, is often able to offer patients first-in-human clinical trials of immunotherapies and other novel cancer therapies, including these two recently opened studies.
Emerging research is finding that immunotherapy may extend survival for some women with triple-negative breast cancer. Providence Cancer Institute, a leader in immunotherapy research, is actively investigating options for this aggressive cancer.
A newly opened Phase 3 study at Providence Cancer Institute hopes to shed new light on the benefits of two immunotherapies, nivolumab and NKTR-214, for patients with advanced melanoma.
Checkpoint inhibitors are showing promise as a potential new line of treatment for people with liver cancer. The Earle A. Chiles Research Institute at Providence Cancer Institute currently has six studies open to liver cancer patients, including two new studies investigating checkpoint inhibitors.
Patients who have relapsed or failed first-line treatment for aggressive forms of B-cell non-Hodgkin lymphoma may qualify to receive a promising CAR T-cell therapy in a new clinical trial at Providence Cancer Institute.
The 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center is now open and blessed! This new space allows us to expand and consolidate our outpatient cancer services in the new Providence Cancer Institute Franz Clinic.
PARP inhibitors are emerging as “one of the promising breakthroughs in experimental oncology,” and have the potential to offer significant benefits for women with BRCA-mutant breast cancers.
From groundbreaking research to innovative treatments to compassionate care, everything we do at Providence Cancer Institute is for you, our patients. That's why we have expanded and consolidated outpatient cancer services on the 11th floor of our Robert W. Franz Cancer Center at Providence Portland Medical Center.
PROVIDENCE CANCER INSTITUTE – It is with deep sadness we announce the passing of Elsie Franz Finley who died Aug. 14, 2018. She was 97 years old.
Recent research has opened up new treatment options for advanced bladder cancer and other urothelial cancers, and clinical trials are contributing to the growing knowledge of how checkpoint inhibitors and other immunotherapies can be most beneficial to patients with this difficult-to-treat disease. At Providence Cancer Institute, four new studies of different immunotherapy approaches are now open to patients.